Faecal microbiota transplantation (FMT) is associated with treatment outcome

Tao Zuo, Sunny H Wong, Kelvin Lam, Rashid Lui, Kitty Cheung, Whitney Tang, Jessica Y L Ching, Paul K S Chan, Martin C W Chan, Justin C Y Wu, Francis K L Chan, Jun Yu, Joseph J Y Sung, Siew C Ng

ABSTRACT

Objective Faecal microbiota transplantation (FMT) is effective for the treatment of recurrent Clostridium difficile infection (CDI). Studies have shown bacterial colonisation after FMT, but data on viral alterations in CDI are scarce. We investigated enteric virome alterations in CDI and the association between viral transfer and clinical outcome in patients with CDI.

Design Ultra-deep metagenomic sequencing of virus-like particle preparations and bacterial 16S rRNA sequencing were performed on stool samples from 24 subjects with CDI and 20 healthy controls. We longitudinally assessed the virome and bacterial microbiome changes in nine CDI subjects treated with FMT and five treated with vancomycin. Enteric virome alterations were assessed in association with treatment response.

Results Subjects with CDI demonstrated a significantly higher abundance of bacteriophage Caudovirales and a lower Caudovirales diversity, richness and evenness compared with healthy household controls. Significant correlations were observed between bacterial families Proteobacteria, Actinobacteria and Caudovirales taxa in CDI. FMT treatment resulted in a significant decrease in the abundance of Caudovirales in CDI. Cure after FMT was observed when donor-derived Caudovirales contigs occupied a larger fraction of the enteric virome in the recipients (p=0.024). In treatment responders, FMT was associated with alterations in the virome and the bacterial microbiome, while vancomycin treatment led to alterations in the bacterial community alone.

Conclusions In a preliminary study, CDI is characterised by enteric virome dysbiosis. Treatment response in FMT was associated with a high colonisation level of donor-derived Caudovirales taxa in the recipient. Caudovirales bacteriophages may play a role in the efficacy of FMT in CDI.

Trial registration number NCT02570477

INTRODUCTION

Clostridium difficile infection (CDI) is a leading nosocomial infection affecting half a million people in the USA. Antibiotic therapy is the first-line treatment, but up to one-third of patients do not achieve a durable response. Recently, faecal microbiota transplantation (FMT) with either fresh or frozen stool from healthy donor has been shown to be highly effective in patients with recurrent CDI with a cure rate of 85%–90%. The efficacy of FMT is mostly based on restoration of the phylogenetic diversity and bacterial microbiota to resemble that of a ‘healthy’ individual. However, the mechanism and long-term effects of FMT remain poorly understood.

Significance of this study

What is already known on this subject?
- Faecal microbiota transplantation (FMT) is highly effective for the treatment of recurrent Clostridium difficile infection (CDI).
- Studies have shown bacterial colonisation after FMT, but data on viral alterations in CDI are scarce.

What are the new findings?
- CDI was characterised by a high abundance of Caudovirales bacteriophages and a low Caudovirales diversity, richness and evenness compared with healthy household controls.
- Donor-derived Caudovirales taxa occupied a significantly larger fraction of the enteric virome in CDI subjects who responded to FMT compared with those who did not.
- FMT was associated with alterations in the enteric virome and bacterial microbiome, while vancomycin treatment was associated with alterations of the bacterial microbiome only.
- Recipients infused with donor faeces consisting of a higher richness of Caudovirales than that of recipient were all cured with FMT. CDI subjects who had restoration of bacterial community only were found to have disease recurrence.

How might it impact on clinical practice in the foreseeable future?
- The restoration of virome community is as important as that of bacterial microbiome in FMT.
- Donor selection based on virome characteristics should be considered in FMT practice.
Humans are also colonised by a large population of viruses, especially bacteriophages that may play a pivotal role in microbiome ecology.\textsuperscript{9,11} Limited studies have reported that bacteriophages can be transferred to recipients from the donor microbiota.\textsuperscript{12–15} In a study of three patients with UC, transfer of multiple viral lineages through FMT was reported.\textsuperscript{13} In a single case report of CDI, virome alterations over time after FMT largely consisted of Caudovirales.\textsuperscript{12,16} Recently, a preliminary investigation of five patients with CDI showed that transfer of sterile faecal filtrates from donor stool was effective to eliminate symptoms.\textsuperscript{15} Overall, these data suggest that other than bacterial components, bacteriophages or bacteriocins are likely contributing to the normal intestinal microenvironment in FMT. Besides, whether patients with CDI have alterations in the enteric virome and the extent of such changes have also not been studied. In this study, we postulate that bacteriophages may interact with host microbes and influence the clinical outcome after FMT. We herein performed ultra-deep virus-like particles’ (VLPs) metagenomic sequencing and 16S rDNA sequencing to determine enteric virome and bacteriophages–bacteria interactions in subjects with CDI compared with healthy controls. We also serially assessed changes in the virome post FMT and examined whether bacteriophage transfer is associated with the clinical outcome of FMT. To our knowledge, this pilot study is the first and largest to date to characterise the enteric virome alterations in CDI and to elucidate changes in viral communities after FMT and its relatedness with treatment outcome.

METHODS

Study subjects and treatment outcome

The current study was a substudy from a randomised controlled trial (RCT) of FMT versus vancomycin for patients with CDI. Consecutive CDI subjects enrolled into this RCT were invited to participate in a substudy of assessment of faecal microbiota. Patients were included if they had three or more loose or watery stools per day for at least two consecutive days, or eight or more soft or loose stools in 48 hours, and a positive stool test for C. difficile based on a two-step testing algorithm in our hospital, a positive GDH (glutamate dehydrogenase) screening test followed by a positive PCR test of C. difficile. A total of 24 subjects with CDI and 20 healthy household controls were recruited, and stool samples at baseline were obtained for analyses of virome and bacterial microbiome. Among them, 14 CDI subjects consented to have stool samples collected serially after treatment for microbiome analysis. Nine CDI subjects were treated with FMT and five were treated with vancomycin, and they were followed up at baseline and weeks 2, 4, 10 and 16 after treatment (see online supplementary figure 1). One patient FMT6 had recurrent CDI. This patient had five previous episodes of CDI prior to FMT. Subjects in the FMT group received oral vancomycin 500 mg four times per day for 10 days. A computer-generated randomisation schedule was used to assign patients to the treatment sequences. All patients kept a stool diary and were questioned about stool frequency and consistency and medication use.

Treatment response was defined as an absence of diarrhoea or persistent diarrhoea that could be explained by other causes with a negative stool test for C. difficile toxin, while relapse was defined as diarrhoea with a positive stool test for C. difficile toxin. Treatment cure is defined as symptom resolution and a complete absence of diarrhoea or other symptoms of diarrhoea without concurrent use of anti-diarrhoeal medications at end of follow-up (last follow-up was referred to as the last stool collection time point, as shown in supplementary figure 1). Six of the nine subjects who had FMT (FMT1–FMT6) and three of the five patients (STD3–STD5) who had vancomycin were cured of CDI (termed responders, table 1) at a median follow-up of 16 weeks. CDI recipients FMT8 and FMT9 shared the same donor, and this donor was termed ‘D8’. Clinical data of the subjects and collected stool samples are shown in online supplementary table S1. None of the patients had received antibiotics or proton pump inhibitors after FMT. The detailed study design and methods of donor recruitment were included in the online supplementary appendix.

Virome data analysis

To estimate contig abundance and calculate sequence diversity, all reads were aligned to the resulting contigs using Bowtie2 (V. 2.2.9).\textsuperscript{18} The mapped sequence counts, contig lengths and total sequence counts were used to normalise the sequence counts and represent the RPKM (reads per kilobase per million) raw data) per sample (sequence statistics in online supplementary table S2). Sequence processing and quality control, de novo contig assembly and taxonomy annotation are included in the online supplementary appendix.

### Table 1 Clinical characteristics and outcomes of subjects who received FMT or vancomycin for Clostridium difficile infections

<table>
<thead>
<tr>
<th>Subject</th>
<th>Sex</th>
<th>Age</th>
<th>Smoking</th>
<th>Severe/ moderate</th>
<th>Duration of follow-up (weeks)</th>
<th>Outcome (till last follow-up)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FMT1</td>
<td>M</td>
<td>80</td>
<td>Ex-smoker</td>
<td>Moderate</td>
<td>16</td>
<td>Cured</td>
</tr>
<tr>
<td>FMT2</td>
<td>M</td>
<td>52</td>
<td>No</td>
<td>Severe</td>
<td>27</td>
<td>Cured</td>
</tr>
<tr>
<td>FMT3</td>
<td>M</td>
<td>38</td>
<td>No</td>
<td>Moderate</td>
<td>17</td>
<td>Cured</td>
</tr>
<tr>
<td>FMT4</td>
<td>F</td>
<td>76</td>
<td>No</td>
<td>Moderate</td>
<td>18</td>
<td>Cured</td>
</tr>
<tr>
<td>FMT5</td>
<td>M</td>
<td>63</td>
<td>No</td>
<td>Severe</td>
<td>18</td>
<td>Cured</td>
</tr>
<tr>
<td>FMT6</td>
<td>M</td>
<td>88</td>
<td>No</td>
<td>Severe</td>
<td>23</td>
<td>Cured</td>
</tr>
<tr>
<td>FMT7</td>
<td>M</td>
<td>45</td>
<td>Ex-smoker</td>
<td>Severe</td>
<td>20</td>
<td>Recurrence at week 19</td>
</tr>
<tr>
<td>FMT8</td>
<td>F</td>
<td>89</td>
<td>No</td>
<td>Moderate</td>
<td>11</td>
<td>Recurrence at week 5</td>
</tr>
<tr>
<td>FMT9</td>
<td>F</td>
<td>38</td>
<td>No</td>
<td>Severe</td>
<td>28</td>
<td>Recurrence at week 28</td>
</tr>
<tr>
<td>STD1</td>
<td>M</td>
<td>88</td>
<td>Ex-smoker</td>
<td>Severe</td>
<td>20</td>
<td>Recurrence at week 12</td>
</tr>
<tr>
<td>STD2</td>
<td>M</td>
<td>93</td>
<td>No</td>
<td>Moderate</td>
<td>7</td>
<td>Recurrence at week 7</td>
</tr>
<tr>
<td>STD3</td>
<td>F</td>
<td>78</td>
<td>Smoker</td>
<td>Severe</td>
<td>14</td>
<td>Cured</td>
</tr>
<tr>
<td>STD4</td>
<td>F</td>
<td>83</td>
<td>No</td>
<td>Severe</td>
<td>17</td>
<td>Cured</td>
</tr>
<tr>
<td>STD5</td>
<td>F</td>
<td>99</td>
<td>No</td>
<td>Moderate</td>
<td>26</td>
<td>Cured</td>
</tr>
</tbody>
</table>

FMT, faecal microbiota transplantation; STD, standard therapy (vancomycin).
of each sample to the contigs. These values were used to generate an operational taxonomic unit (OTU) relative abundance table, which was annotated with the taxonomy described above. The virome abundance data were imported into R 3.2.3. Richness, diversity and rarefaction calculation were performed using the estimated richness function of the phyloseq package. Diversity and richness plots were generated in GraphPad Prism (V 6.0). Spearman correlations and their significance were calculated using the cor and cor.test functions in R, respectively. For the Caudovirales–bacterial taxa comparisons, Spearman correlations were calculated for the relative abundance of the 50 most abundant Caudovirales and the bacterial families determined to be significantly associated with disease by LEfSe analysis. Correlation plots were generated using the corrplot R package. Heat maps were generated using the pheatmap R package. LEfSe linear discriminant analysis and multivariate analysis are included in the online supplementary appendix.

Species and contig presence
To establish the presence of a species or a contig within a sample, the RPKM of a contig or a species is set to be >2 (a stringent criteria), so as to rule out the false-positive finding) for the contig or the species to be assured as present within a sample. In samples after FMT, if a contig or a species was not present in the recipient baseline sample but present in the corresponding donor baseline sample and in the recipient post-FMT sample, the contig or species was defined as ‘donor-derived’; if a contig or a species was not present in the corresponding donor baseline sample but detected both in the recipient baseline sample and in the recipient post-FMT sample, the contig or the species was defined as ‘recipient-exclusive’; if a contig or a species was present across the recipient baseline sample, the contig or a species was de

Donor Caudovirales richness and treatment response
Given that Caudovirales was the most abundant and significantly changed viral taxon in patients with CDI, we focused on Caudovirales hereafter and studied the effect of donor Caudovirales richness on treatment response. In subjects FMT1, FMT3, FMT5 and FMT6, whereby the Caudovirales richness of the donor was higher than that of the recipient (figure 3A),
all recipients were cured. These recipients also showed an increase in the diversity of Caudovirales after FMT, though it is not consistent in the richness change post FMT (figure 3A, B). In these four CDI subjects who responded to FMT, the Caudovirales contigs found in the donor baseline sample out-numbered that of the contigs in the recipient baseline stool sample (figure 3C), further substantiating that donor Caudovirales richness was higher than that of the recipient. In contrast, when the Caudovirales richness of the donor was lower than that of the recipient (FMT2, FMT4, FMT7, FMT8 and FMT9), the treatment outcome was not consistent across the recipients. FMT2 and FMT4 responded to treatment, but FMT7, FMT8 and FMT9 did not. The Caudovirales diversity and richness alterations post FMT were inconsistent among these subjects. The simultaneous treatment failure in subjects FMT8 and FMT9, where they shared the same donor, provided a valuable piece of evidence for a donor effect with regard to virome on FMT efficacy. Overall, we found that when the Caudovirales richness of the donor was higher than that of the recipient, all the CDI subjects achieved a response to FMT.

Transfer of Caudovirales bacteriophages from donor to recipient and treatment response

We next assessed the presence of donor-derived Caudovirales in relation to treatment response. A larger proportion of Caudovirales contigs was transferred from the donor to the recipient detected at the last follow-up stool in FMT responders than in FMT non-responders (figure 4A, B). Donor-derived
Caudovirales occupied a significantly larger fraction (>20%) of the virome in the FMT responders than in the non-responders (<20%) (figure 4B,C, Mann-Whitney test, p<0.05). A similar and consistent pattern was also observed at the species level (see online supplementary figure 5A). Moreover, the presence of donor-derived Caudovirales contigs in the recipients remained sustainable over time after FMT. FMT responders consistently exhibited higher levels of donor-derived Caudovirales contig colonisation throughout the follow-up period when compared with FMT non-responders (see online supplementary figure 5B). Thus, the quantity and final proportion of donor-derived Caudovirales in the recipient appeared to be associated with treatment outcome of FMT.

We also investigated bacterial transfer after FMT and correlated that with treatment outcome. We found increased frequency of bacterial families in the stool of CDI subjects after FMT, which included Lachnospiraceae and Ruminococcaceae (see online supplementary figure 6A,B). However, there was no significant difference in the frequency of donor-transferred bacterial OTUs between FMT responders and FMT non-responders (figure 4D,E). In two subjects who had early CDI recurrence (FMT7 and FMT8), a lower abundance of donor-transferred bacteria and a lack of increase in the bacterial diversity and richness were observed after FMT (see online supplementary figure 6B,C). These two subjects also had a low Caudovirales colonisation. Hence, early disease recurrence in FMT7 and FMT8 after FMT might be related to a lack of colonisation of both bacteria and viruses. Subject FMT9 experienced disease recurrence at week 28. This subject had low levels of Caudovirales taxa colonisation throughout the post-FMT follow-up stool samples even though there was an increase in bacterial diversity and richness and substantial bacteria colonisation after FMT (see online supplementary figure 6B,C). Overall, FMT responders had a lower colonisation of Caudovirales bacteriophages than non-responders. These data suggest a role of bacteriophages in the efficacy of long-term FMT outcomes.

Figure 2. Alterations in the enteric virome after faecal microbiota transplantation (FMT). (A) Relative abundance of Caudovirales, Microviridae, and Anelloviridae in pre-FMT samples and post-FMT samples collected at the last follow-up. Statistical significance was determined by paired Wilcoxon sign permutation test, *p<0.05. (B) Alterations in the relative abundance of viral species in the stool of Clostridium difficile infection subjects after FMT at different time points until the last follow-up. ‘F’ indicates FMT-treated subject. ‘D’ indicates FMT donor. ‘W’ indicates weeks post treatment.
We further assessed the presence of donor-derived contigs within each Caudovirales species along with the change in the abundance of these species after FMT. FMT responders acquired more donor-derived contigs within the Caudovirales species when compared with non-responders (see online supplementary figure 7A). Not all the relative abundance of Caudovirales species was significantly enhanced with the colonisation of corresponding Caudovirales contigs from the donor (see online supplementary figure 7A), which indicates that the newly formed Caudovirales ecosystem post FMT was based on a more intricate interaction network. Furthermore, not all transfer of Caudovirales contigs from donor was dependent on a high donor-to-recipient ratio of abundance of species (see online supplementary figure 7B).

**Virome alterations in patients with CDI after vancomycin treatment**

We assessed the impact of vancomycin treatment (STD) on the virome and bacterial microbiome in five patients with CDI...
Figure 4  Transfer of Caudovirales bacteriophages and faecal microbiota transplantation (FMT) treatment outcome. (A) Presence–absence heat map of Caudovirales contigs in pre-FMT and post-FMT collected at the last follow-up for nine FMT recipients. Only contigs with reads per kilobase per million > 3 were shown to assure the colonisation of donor-derived contigs. Red lines indicate contigs transferred from the donor. (B) Percentage of donor-transferred Caudovirales contigs in FMT recipients at the last follow-up. The size of the circle indicates the count of Caudovirales contigs transferred from donor. The colour of the circle indicates the richness of Caudovirales in the recipient relating to the treatment response. (C) Comparison of the frequency of donor-derived Caudovirales contigs in FMT responders and in non-responders. Statistical significance was determined by Mann-Whitney test. *p<0.05. (D) Presence of bacterial operational taxonomic unit (OTUs) in FMT recipients at the last follow-up. The colour of the bar indicates the origin of the bacterial OTUs. Purple indicates donor-derived OTUs colonised in the recipient, orange indicates OTUs exclusively present in recipient but not in the donor, while green indicates OTUs present both in donor and in recipient. (E) Comparison of the frequency of donor-derived bacterial OTUs in FMT responders and in non-responders. Statistical significance was determined by Mann-Whitney test.
responded with an increase in the relative abundance of these taxa positively related to Caudovirales as well as a correlation between bacterial diversity and richness over the course of vancomycin treatment. A significant correlation between bacterial diversity and richness was observed in vancomycin responders. In FMT responders, a correlation was found between Caudovirales diversity and richness as well as a correlation between bacterial diversity and richness (supplementary figure 8B). Moreover, marginally significant inverse correlations were observed between Caudovirales richness and bacterial diversity, and between Caudovirales richness and bacterial richness in patients after FMT but not after vancomycin treatment. These data suggest that FMT has a synergistic effect on both the bacterial and viral component of the gut microbiome whereas vancomycin may predominantly affect the bacterial microbiome. We performed taxonomical analysis to further elaborate the effects of vancomycin on the virome community. In CDI subjects who responded to vancomycin, the virome structure was not significantly altered over time, whereas marked oscillation of the virome was seen in subjects who did not respond to vancomycin (supplementary figure 8C). Moreover, Caudovirales abundance was increased after vancomycin treatment, but decreased after FMT (supplementary figure 8D). To define the differentially enriched viral species between FMT and vancomycin responders, we implemented a LEfSe analysis across all the follow-up samples of treatment responders. A multitude of overpresented viral species was observed in the vancomycin samples, and nearly half of them belonged to Caudovirales (supplementary figure 9).

Virome and bacterial microbiome interactions in patients with CDI before and after FMT

To characterise the relationship between the configuration of virome and that of the bacterial microbiome, we evaluated the correlation of the diversity and richness of Caudovirales with that of bacterial communities in household controls and in patients with CDI. In controls, there was a significant correlation between Caudovirales diversity and bacterial diversity (Spearman’s \( \rho = 0.511, p<0.05 \)), and between Caudovirales diversity and bacterial richness (Spearman’s \( \rho = 0.625, p<0.05 \)) (figure 5A). However, these correlations were distorted in CDI. After FMT, we demonstrated a shift of the microbiome community from a low to high bacterial richness and diversity, and from a low to a high Caudovirales diversity (figure 5B). The microbiome of FMT non-responders changed less when compared with FMT responders. The temporal restoration of bacterial structure over the period of follow-up in subject FMT9 indicated bacterial reset, but disease recurrence at week 28 may be associated with unaltered virome structure after FMT. We further assessed the correlation of Caudovirales species with bacterial families in CDI subjects and controls. More positive correlations, particularly of bacterial families Proteobacteria and Actinobacteria with Caudovirales species, were found in CDI than in controls (see online supplementary figure 10). This corresponded with an increase in the relative abundance of these bacterial taxa in patients with CDI together with an overpresentation of Caudovirales taxa compared with controls. Among the Caudovirales taxa positively related to Proteobacteria, predominant bacteriophage species comprise Burkholderia phage, Planktotrichix phage, Pseudomonas phage, Moraxella phage and Halomonas phage.

We lastly investigated alterations in the bacteria–Caudovirales relationship in FMT responders. Pre-FMT samples showed a mutualistic relationship, particularly of Proteobacteria–Caudovirales and Actinobacteria–Caudovirales (figure 5C). However, a contraction of the number of significant correlations after FMT was observed between CDI-enriched bacteria and Caudovirales taxa. Interestingly, a few inverse correlations emerged after FMT, further implicating the importance of a ‘favourable’ virome–bacterial microbiome relationship. These results suggest a distinct virome–bacterial microbiome relationship before and after FMT treatment.

**DISCUSSION**

To date, this study represents the most in-depth human gut virome study of FMT. In this pilot observational study, we showed that patients with CDI exhibited a state of enteric virome dysbiosis, characterised by an increased Caudovirales abundance and a decreased Caudovirales diversity, richness and evenness. The mechanism underlying the efficacy of FMT has been attributed to improved microbial diversity with re-establishment of a ‘normal’ bacterial microbiota as a host defence against *C. difficile.* Recently, Ott and colleagues showed that sterile faecal filtrate transfer was effective in treating five subjects with CDI, which highlights the therapeutic potential of other components including bacteriophages within the faecal matters other than bacteria. In this preliminary study, the observation that disease cure was associated with Caudovirales bacteriophage colonisation and donor Caudovirales richness provides new insights into the potential importance of virome derived from donor that may influence treatment outcome. Our data further highlight a new concept to FMT in that bacteriophages may be critical components of FMT. Bacteriophages have the potential to alter the composition and function of host microbiota and influence treatment outcomes. In particular, correlations between specific bacteriophages and bacteria shown in this study appeared to be associated with the outcome of FMT in CDI.

Among the enteric virome, Caudovirales is the most abundant taxon. Studies have shown that enteric Caudovirales were associated with intestinal inflammation although the underlying mechanisms remain largely unknown. Patients with IBD have been shown to have a significantly higher Caudovirales richness than healthy household controls, which is in contrast with the decreased Caudovirales richness observed in CDI subjects. Virome dysbiosis seen in CDI appeared to be disease-specific and was not observed in stool of subjects with norovirus-associated diarrhoea. Unlike the high cure rate of FMT in CDI, only up to a quarter of patients with UC, a subtype of IBD, achieved a sustained response with FMT. One plausible hypothesis is that a higher Caudovirales richness in donor than diseased recipient is important for FMT efficacy. In line with this hypothesis, we found that when donor Caudovirales richness was higher than that of the recipient, all the recipients responded to FMT, while more than half of the recipients whose Caudovirales richness was higher than that of the donor (three out of the five) experienced disease recurrence after FMT treatment. This finding suggests a donor effect of FMT efficacy and highlights that future FMT therapy should take into consideration detailed characterisation of donor and recipient faecal virome, although these findings need to be confirmed in a larger cohort. As this study has a modest sample size and we were unable to prove causation between donor
Caudovirales richness, transfer of bacteriophages and FMT treatment outcome, it remains unclear whether altered bacteriophages represent a primary or secondary phenomenon. Understanding how Caudovirales bacteriophage transfer and donor virome richness affect FMT responses in CDI could help us understand their effects for treatments of other human diseases.

Activated phages can drive disease by reducing bacterial diversity and spreading virulence factors and antibiotic resistance.\(^{25}\) The expansion of Caudovirales abundance in CDI could arise from the induction of prophage from commensal microbes, according to the ‘predator–prey’ model by Lotka-Volterra in which bacterial phage prey on bacteria resulting in the release of bacteriophages after bacteria enter into the lytic cycle.\(^{26,27}\) Disparately expanded Caudovirales taxa may lead to decreased diversity and evenness in CDI compared with that in controls. Correlation of CDI-enriched bacteria with Caudovirales species in CDI and a reset of correlation after FMT indicate a ‘kill-the-winner’ dynamics, where upregulated Caudovirales bacteriophages were observed with the overpresentation of certain bacterial taxa enriched in CDI.\(^{28}\) Our data showed that restoration of a balanced relationship between bacterial microbiome

---

**Figure 5** Bacteria–Caudovirales relationship pattern (A) The correlation of bacteria richness with Caudovirales diversity and bacteria diversity with Caudovirales diversity in Clostridium difficile infection (CDI) and controls, respectively. Linear regression±95% CI, Spearman correlation coefficient and p value are shown. (B) The correlation of bacteria richness with Caudovirales diversity and bacteria diversity with Caudovirales diversity before and after faecal microbiota transplantation (FMT). (C) Bacteria–Caudovirales correlation pattern during FMT treatment. Spearman correlation plots of the relative abundances of Caudovirales species and bacterial families identified to be significantly associated with CDI and controls, in donor, pre-FMT and post-FMT samples. Statistical significance was determined for all pairwise comparisons; significant correlations (p<0.05) are displayed with asterisk. Blue circles and positive values indicate positive correlations, and red circles and negative values indicate inverse correlations. The size and shading indicate the magnitude of the correlation, where darker shades are more correlated than lighter ones.


Gut microbiota
and virome is important after FMT. It is notable that virome alterations in concert with bacterial changes after FMT may influence the efficacy of FMT in CDI.

Many patients with CDI often undergo multiple rounds of antibiotic therapy before undergoing FMT. This may lead to phage activation and act as a confounder. However, this scenario is unlikely as we included subjects on vancomycin as a control group and reported that the virome showed little variation over the course of treatment in subjects who responded to vancomycin.

This observational study had a modest sample size. However, to our knowledge, it represents the largest study to date that comprehensively followed CDI subjects after FMT and assessed intestinal viral dysbiosis after FMT therapy. Sustained intestinal viral dysbiosis after FMT and assessed comprehensively followed CDI subjects after FMT and assessed to our knowledge, it represents the largest study to date that comprehensively followed CDI subjects after FMT and assessed intestinal viral dysbiosis after FMT, due to limited amount of Caudovirales transfer from the donor, could be a potential factor that predisposes patients towards disease recurrence. These findings contribute to our knowledge on ‘optimal’ donor selection and highlight that future FMT therapy may consider detailed characterisation of donor and recipient faecal virome.

In conclusion, this pilot study showed that treatment response in FMT was associated with a high colonisation level of donor-derived Caudovirales taxa in the recipient, especially when Caudovirales richness in the donor was higher than that of the recipient. Our data suggest that establishing a bacteria and virome structure that more closely resembles that of healthy controls through FMT may be important to eradicate CDI.

**Accession codes:** Sequence data have been deposited to the NCBI Sequence Read Archive under BioProject accession number PRJNA353587 and PRJNA3535980.

**Contributors** TZ performed the experiments, metagenomic analysis and drafted the manuscript. SHW performed FMT in clinic, helped virome analysis and revised the manuscript. KC collected the clinical samples and data. JYLC managed the clinical practice and clinical database. MC provided the virome sequencing data of patients with norovirus infection. PKSC, JCYW, KL and RL assisted in FMT and revised the manuscript. MC provided the virome sequencing data of patients with norovirus infection. PKSC, JCYW, KL and RL assisted in FMT and revised the manuscript. SHW performed FMT in clinic, helped virome analysis and revised the manuscript. contributers.

**Funding** Hong Kong Society of Gastroenterology.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** The Joint Chinese University of Hong Kong, New Territories East Cluster Clinical Research Ethics Committee.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**REFERENCES**


